Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results

Dateline City:  WHITEHOUSE STATION, N.J. 2012 Full-Year Non-GAAP EPS of $3.82, Excluding Certain Items; GAAP EPS of $2.16; Fourth-Quarter Non-GAAP EPS of $0.83, Excluding Certain Items; GAAP EPS of $0.46 2012 Full-Year Worldwide Sales Were $47.3 Billion, a Decrease of 2 Percent, Including a 3 Percent Unfavorable Impact from Foreign Exchange; Fourth-Quarter Worldwide Sales Were $11.7 Billion, a Decline of 5 Percent, Including a 2 Percent Unfavorable Impact from Foreign Exchange Full-Year and Fourth-Quarter Double-Digit Global Sales Growth for JANUVIA, JANUMET, GARDASIL, VICTRELIS and ZOSTAVAX Offset the Decline in SINGULAIR Sales Following Patent Expiry in the United States Provides Update on Odanacatib Program; Now Anticipates Filing in 2014 2013 Full-Year Non-GAAP EPS Target of $3.60 to $3.70, Excluding Certain Items; GAAP EPS Range of $2.03 to $2.26 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012. Language:  English Contact HTML:  MerckMedia Contacts:Ron Rogers, 908-423-6449Steve Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 ...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Authors: Tags: Corporate News Financial News Source Type: news

Related Links:

The Advisory Committee on Immunization Practices (ACIP) recommends that adults aged ≥19 years receive various vaccines to prevent serious health conditions, including hepatitis B, herpes zoster/shingles, human papilloma virus (HPV), and pneumonia. Recent vaccine approvals by the US Food and Drug Administration (FDA) have led to updates in the ACIP adult immunization schedule. Thi s article provides a relevant clinical literature review for nurse practitioners on the newly approved vaccines for hepatitis B and herpes zoster and updated ACIP recommendations.
Source: The Journal for Nurse Practitioners - Category: Nursing Authors: Tags: Featured Article Source Type: research
ConclusionsSOPs may provide a good starting point for increasing adult immunization coverage rates. Using additional interventions, quality-based metrics, or incentives could lead to sustained adult immunization prioritization.
Source: American Journal of Infection Control - Category: Infectious Diseases Source Type: research
Purpose of review Kidney transplant recipients are at high risk of contracting infections, some of which are considered vaccine-preventable, because of their highly immunosuppressed state. In this vulnerable group of patients, infection can lead to poor outcomes including graft failure and death, thus vaccination in the posttransplant population is an important strategy in order to mitigate this risk. The present review is aimed at providing an update on recent advances with respect to vaccination strategies in kidney transplant recipients. Recent findings General principles behind vaccination in kidney transplantatio...
Source: Current Opinion in Nephrology and Hypertension - Category: Urology & Nephrology Tags: DIALYSIS AND TRANSPLANTATION: Edited by Anil Chandraker and J. Kevin Tucker Source Type: research
Felicia D. Goodrum Sterling Heidi L. Pottinger By FELICIA D. GOODRUM STERLING, PhD and HEIDI L. POTTINGER, DrPH, MPH, MA The measles outbreak in Washington state this week has brought new attention to the anti-vaccine movement.  In fact, the World Health Organization recently identified “vaccine hesitancy” as one of top threats to global health. In the US, the number of unvaccinated children has quadrupled since 2001, enabling the resurgence of infectious diseases long-since controlled.  In fact, the WHO claims a staggering 1.5 million deaths could be prevented worldwide by improved vaccination rates....
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Patients Felicia Goodrum Sterling Global Health Heidi L. Pottinger public health The OpEd Project vaccines Source Type: blogs
Abstract As primary care providers and experts on diseases affecting the skin, such as herpes zoster (shingles) and human papillomavirus-related cancers, dermatologists are often asked to make important recommendations on vaccines and vaccinations; however, a rise in antivaccine attitudes-sometimes referred to as "vaccine hesitancy"-among patient populations, especially in North America and Europe, has created new challenges for the practicing dermatologist. Here we provide a brief overview of some of the major evidence that refutes commonly held misperceptions about vaccines. PMID: 30207522 [PubMed - in process]
Source: Skinmed - Category: Dermatology Authors: Tags: Skinmed Source Type: research
Purpose of review To review the latest data in the field of vaccinations in systemic lupus erythematosus (SLE), focusing on pneumococcal, seasonal influenza, herpes zoster and human papillomavirus infections. Recent findings Less than 40% of patients responded adequately to the 23-valent pneumococcal polysaccharide (PPS23) vaccine. A randomized controlled trial showed that sequential administration of the pneumococcal conjugate vaccine followed by the PPS23 vaccine was well tolerated but was not superior to the PPS23 vaccine alone in terms of immunogenicity. A real-life observation confirmed that annual influenza vacc...
Source: Current Opinion in Rheumatology - Category: Rheumatology Tags: SYSTEMIC LUPUS ERYTHEMATOSUS AND SJöGREN SYNDROME: Edited by Mariana J. Kaplan Source Type: research
Abstract After decades of slow progress, the last years have seen a rapid acceleration of the development of adjuvanted vaccines which have lately been approved for human use. These adjuvants consist of different components, e.g. aluminium salts, emulsions such as MF59 and AS03, Toll-like receptor (TLR) agonists (CpG ormonophosphoryl lipid A (MPL) adsorbed on aluminium salts as in AS04) or combination of immunopotentiators (QS-21 and MPL in AS01). Despite their distinctive features, most of these adjuvants share some key characteristics. For example, they induce early activation (although at different levels) of i...
Source: Seminars in Immunology - Category: Allergy & Immunology Authors: Tags: Semin Immunol Source Type: research
Date: May 7, 2018 Issue #:  1546Summary:  The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with acellular pertussis (Tdap), measles/mumps/rubella (MMR), varicella (VAR), herpes zoster (RZV; ZVL), human papillomavirus (HPV), and pneumococcal conjugate (PCV13) and polysaccharide (PPSV23) vaccines. For adults with certain medical conditions or occupational, behavioral, or other risk factors, hepatitis A (HepA), hepatitis B (HepB), meningococcal (MenAC...
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: ActHIB Avaxim Bexsero Boostrix Cervarix diphtheria Engerix-B Gardasil Gardasil9 Genital warts Haemophilus infuenzae Havrix hepatitis a hepatitis b Heplisav-B Hiberix HPV vaccine Influenza vaccine measles Menactra Me Source Type: research
Quite a high number of new vaccines have been introduced into the global healthcare programme during the past 15 years. Among them vaccines against Streptococcus pneumonia, rotavirus, human papillomavirus, Neisseria meningitides, varicella zoster virus (responsible for herpes zoster), dengue, and new ones against influenza viruses [1], are now in the market, but others against malaria and Ebola are coming soon [2].
Source: Health Policy - Category: Health Management Authors: Source Type: research
Abstract PROBLEM/CONDITION: Overall, the prevalence of illness attributable to vaccine-preventable diseases is greater among adults than among children. Adults are recommended to receive vaccinations based on their age, underlying medical conditions, lifestyle, prior vaccinations, and other considerations. Updated vaccination recommendations from CDC are published annually in the U.S. Adult Immunization Schedule. Despite longstanding recommendations for use of many vaccines, vaccination coverage among U.S. adults is low. PERIOD COVERED: August 2014-June 2015 (for influenza vaccination) and January-December 20...
Source: MMWR Surveill Summ - Category: Epidemiology Authors: Tags: MMWR Surveill Summ Source Type: research
More News: Cervical Cancer Vaccine | Janumet | Januvia | Merck | Pharmaceuticals | Shingles (Herpes Zoster) Vaccine | Singulair | Varicella-Zoster Virus Vaccine